Designation Underscores Unmet Medical Need for Life-Threatening Seizure Condition July 22, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central …
Lundbeck Completes Acquisition of Chelsea Therapeutics
NORTHERA™ (droxidopa) is expected to be available to patients in the U.S. during the fall of this year June 24, 2014 H. Lundbeck A/S (Lundbeck) …
SAGE Therapeutics Appoints Howard H. Pien to the Company’s Board of Directors
Pien Brings Expansive Commercial Expertise to SAGE’s Rapidly Advancing Pipeline April 1, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare …
SAGE Therapeutics Closes $38M Oversubscribed Series C Financing
March 13, 2014 SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the …
Third Rock Ventures Launches Voyager Therapeutics with $45 Million Series A to Develop Life-Changing Gene Therapies for CNS Disorders
February 12, 2014 Third Rock Ventures, LLC announced the formation of Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the …